European Conference for Clinical Nanomedicine — 23-25 May 2011

 19 May 2011

The 4th European Conference for Clinical Nanomedicine is taking place from 23 to 25 May, 2011 in Basel, Switzerland, organised by the CLINAM Foundation, in collaboration with the European Technology Platform on Nanomedicine (ETPN).

The conference focuses on the clinical application of novel developments in nanosciences. It also includes industrial topics, opinions and recommendations from regulatory authorities as well as discussion panels on ethical questions and the wider societal implications.

Joint work with nanomedicine institutional stakeholders

The non-profit organisation CLINAM Foundation is the leading partner organising this major conference on Nanomedicine in Europe and works in collaboration with the European Technology Platform on Nanomedicine (ETPN) and the European Medicines Agency (EMA). Further partners are the European Society for Nanomedicine (ESNAM) and the European Science Foundation (ESF).

ETPN’s focus

The ETP Nanomedicine is organising 3 of 23 sessions held during the conference. The emphasis is on European Policy and funding, industrial challenges and projects’ proposals for joint collaborative research:

  • Strategic Vision, Future Joint Research and Translation of Results, Needs for Policy Initiatives for the Benefit of the Patient. 24th May 2011 – 11:15;
  • Industrial Perspectives of Nanomedicine 2011 – 2020
    Round table with six representatives from academia and industry
    24th May 2011 – 12:00
  • ETPN Flash Proposals Session. Presentation of ideas for collaborative research projects
    25th May 2011 – 10:45

Further information

For more information on the conference see: www.clinam.org

About ETPN

The European Technology Platform on Nanomedicine was established in 2005 as a joint venture of the European Commission, large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of medical nanotechnology. The ETPN contributed to the set up of numerous European-funded projects. The aim is to reach an efficient translation of R&D results into innovative products and to set the dialog with European legislation and regulations authorities.

 

To top